BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 85.88% | 173.38% | -- | -- | 54,186.80% |
| Total Receivables | 265.00% | 376.54% | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 427.38% | 119.72% | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 88.57% | 172.47% | -- | -- | -- |
|
|
|||||
| Total Current Assets | 88.57% | 172.47% | -- | -- | -- |
| Net Property, Plant & Equipment | -6.04% | 570.61% | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 120.84% | 148.12% | -- | -- | -- |
| Total Assets | 178.74% | 172.90% | -- | -- | -- |
|
|
|||||
| Total Accounts Payable | 230.96% | -55.30% | -- | -- | -- |
| Total Accrued Expenses | 86.09% | 152.45% | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 8,866.67% | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -83.43% | -85.12% | -- | -- | -- |
| Total Other Current Liabilities | -83.43% | -85.12% | -- | -- | -- |
| Total Current Liabilities | 79.83% | 78.96% | -- | -- | -- |
|
|
|||||
| Total Current Liabilities | 79.83% | 78.96% | -- | -- | -- |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -20.32% | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 69.92% | 90.42% | -- | -- | -- |
|
|
|||||
| Common Stock & APIC | 1,640.39% | 1,663.17% | -- | -- | -- |
| Retained Earnings | -63.00% | -60.24% | -- | -- | -- |
| Treasury Stock & Other | -613.61% | -95.40% | -- | -- | -- |
| Total Common Equity | 286.11% | 330.13% | -- | -- | -72.98% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | 208.34% |
|
|
|||||
| Total Common Equity | 286.11% | 330.13% | -- | -- | -72.98% |
| Total Preferred Equity | -- | -- | -- | -- | 208.34% |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 202.33% | 184.06% | -- | -- | 1,236.67% |
|
|
|||||